Retractable Fingertip Blades and Inset Mirrored Lenses in Three Chiba City Black Clinics, 2036–2043: A Retrospective Surgical Case Series

1. Introduction

In street usage, a razorgirl is a street samurai, usually a woman, who has been fitted with two signature augmentations. The first is a set of double-edged blades housed beneath the fingernails that extend from and retract into the fingertips. The second is a pair of mirrored lenses inset surgically over the eye sockets, sealing them. The pairing is familiar in Chiba City and in the Sprawl, and it is associated with bodyguard work and contract violence. Its surgery, though, has almost no published record. This paper calls the two operations fingertip blade implantation and inset mirrored-lens implantation. When both are performed on one patient within ninety days, we call them the combined procedure.

Almost all such work is done in the black clinics of Chiba City, in Night City and around Ninsei. These clinics operate outside licensed medicine but are tolerated, and they are known chiefly for nerve-splicing and a trade in transplant organs. Access to licensed care depends on employment. Zaibatsu employees receive augmentation, where their employer wants it, through corporate clinics with licensed staff and continuous post-operative care. Street operators have no such provision. Survey work on the street augmentation market finds that razorgirl procedures are financed by personal debt to clinic-affiliated lenders or by contract work in the puppet houses, where a worker rents out her body while a neural cutout suppresses her awareness during sessions. For such patients, the relevant clinical question is how outcomes inside the black-clinic sector can be improved. Whether that sector should exist is a separate matter, and this paper does not argue it.

Prior Consortium case reports have described wide variation in post-operative protocol across Chiba clinics, but they did not relate that variation to outcome. We therefore audited registry outcomes for combined procedures at three cooperating clinics. We asked what proportion integrate successfully, at which anatomical site complications arise, and whether complication rates differ between clinics. The records span procedures from 2036 to 2043 with follow-up to 2045. We write from the years after the Straylight run, when the registry's post-operative series became complete enough for this analysis.

2. Methods

Records came from the Chiba City Black Clinic Case Registry, accession series RG-2036. Three member clinics, two in Ninsei and one elsewhere in Night City, agreed to release anonymised operative and follow-up notes. We refer to them as Clinics A, B and C. They were not chosen at random: they are the Consortium members that had kept structured follow-up records throughout the period. All adult patients who received the combined procedure between January 2036 and December 2043 were screened (n = 72; Clinic A 28, Clinic B 24, Clinic C 20). One of us (F.C.) is affiliated with the Consortium but did not operate on any patient in the series.

The clinics' operative notes describe a consistent technique, which we summarise as clinic-reported practice. The blade assembly is seated in the distal phalanx beneath the nail bed and enclosed in a cultured, non-autologous tissue sleeve that anchors the housing to bone and soft tissue. Extension is driven by a small actuator in the finger pad, which is linked to the flexor nerve supply by a spliced neural interface so that the blades respond to deliberate muscular signals. Blade dimensions appear only in clinic records and are not analysed here. For lens implantation, the clinic seats a mirrored lens unit in each orbit, seals the socket and reroutes the tear ducts. The notes also record that vision is enhanced through the lens unit, but we treat this as the clinics' own claim and did not assess it.

Integration success, the primary outcome, was defined as functional and complication-free status at a follow-up visit at least 18 months after the later of the two operations. Patients without such a visit were excluded from the primary analysis. There were 14 of them: 3 died of causes that the registry does not specify, and 11 did not return. The analysed cohort therefore numbered 58 (Clinic A 24, Clinic B 19, Clinic C 15). For the worst-case sensitivity analysis, all 14 excluded patients were counted as failures.

Each complicated case was assigned to one primary site of failure, blade implant or lens, according to the first complication recorded. A patient could not appear in both categories. Blade-site rejection was subclassified by location as nail-bed housing sleeve, actuator bed or neural interface. We record secondary events at the other site but do not analyse them. Clinic-reported outcomes were checked against the original visit notes, which survived for 49 of the 58 patients. Four discrepancies were found, and in each case the visit note was treated as authoritative.

Proportions are reported with Wilson 95% confidence intervals. Integration success and blade-site rejection were compared across the three clinics with Fisher's exact test on 3 × 2 tables, because several expected cell counts were below five. The licensed-sector comparator is a published series of fingertip blade implantation performed on its own in corporate clinics. It is presented descriptively.

3. Results

Of the 58 patients analysed, 41 met the definition of integration success at 18 months (70.7%; 95% CI 58.0–80.8%). Under the worst-case assumption, success fell to 41 of 72 (56.9%; 95% CI 45.4–67.7%). The remaining 17 patients were complicated cases.

Blade-site rejection was the primary failure in 11 of the 17 complicated cases (64.7%; 95% CI 41.3–82.7%). The lens site accounted for 6 (35.3%; 95% CI 17.3–58.7%). Among the 11 rejections, 7 arose in the nail-bed housing sleeve, 3 in the actuator bed and 1 at the neural interface. Onset times are counted from the date of blade implantation for blade-site events and from the date of lens implantation for lens-site events. Rejection began between weeks 6 and 22, with a median onset at week 11, and 8 of the 11 began between weeks 8 and 14. Lens-site failures clustered much earlier: 4 of 6 occurred within four weeks of lens implantation. Three of the six were failures of the socket seal with infection, two were obstruction of the rerouted tear duct, and one was failure of the lens unit itself. Seal and tear-duct problems were also the dominant early lens complications in an earlier surgical series on orbital sealing and lacrimal rerouting, and our small count fits that pattern. A secondary complication at the other site was recorded in 2 of the 17 cases.

Integration success was 19/24 (79.2%) at Clinic A, 13/19 (68.4%) at Clinic B and 9/15 (60.0%) at Clinic C. This difference was not statistically significant (Fisher's exact test, p = .41). Blade-site rejection followed the same ordering: 2/24 (8.3%; 95% CI 2.3–25.8%) at Clinic A, 4/19 (21.1%; 95% CI 8.5–43.3%) at Clinic B and 5/15 (33.3%; 95% CI 15.2–58.3%) at Clinic C (p = .14). Clinic A was the only clinic to follow a written post-operative schedule with fortnightly review of the finger sites through week 16. The other two reviewed patients only when they returned with symptoms. The confidence intervals for the three clinics overlap widely, and the table gives the full breakdown.

The licensed-sector comparator reports 274 of 311 fingertip blade implantations as integrated at 18 months (88.1%; 95% CI 84.0–91.2%). The two intervals do not overlap. This comparison is between a single corporate-clinic procedure and a combined black-clinic procedure, however, so it measures more than the difference between sectors.

4. Discussion

The main finding is where combined procedures fail. The lens units and their socket seals account for about a third of complicated cases, and the optical hardware failed in only one patient. Most failures come from the host's reaction to the tissue sleeve that anchors the blade housing beneath the nail. A courier-implant failure series from the same registry likewise found device malfunction behind only about a quarter of failures, with most arising outside the hardware, in custody of the client-held retrieval key. In the present series, the concentration of blade-site rejection after the second post-operative month points attention away from device quality and toward post-operative follow-up.

Blade-site rejection followed a time course that fits what is known about non-autologous tissue in patients who receive no immunosuppression. A marker cohort of bioware graft recipients from Ninsei clinics found that many grafts pass through a phase of immune activity in weeks 8–10. That activity either resolves by week 14 or persists and predicts failure. Most rejection in our series began in the same window. We propose, as a hypothesis, that the cultured housing sleeve follows the same path, so that a blade-site rejection is a sleeve that failed to reach delayed tolerance. One difficulty is timing: the median clinical onset here was week 11, so most rejections were already apparent before a week 14 reading could be taken. Any value of monitoring would therefore lie in marker sampling at weeks 8–10, which might flag subclinical activity, combined with the week 14 status check for sleeves that remain quiet. Rejection markers of the kind developed for non-autologous subdermal grafts could serve, although the bioware cohort's week 14 signal itself awaits prospective validation.

Caution is needed in reading the clinic comparison. Clinic A had the only structured monitoring schedule and the lowest rejection rate, but the difference between clinics was not significant, and 58 patients across three sites give little power to detect one. Clinic A may also differ in its patients, its surgeons or its tissue suppliers. Our data are compatible with a benefit from structured monitoring, but they do not show one. The harm-reduction recommendation that follows is a prospective comparison. Consortium clinics would adopt a common schedule of finger-site review across weeks 8–16, which covers the onset window and matches Clinic A's existing schedule, with registry follow-up, and outcomes would be compared with those of clinics that monitor only when patients present with symptoms.

The benchmark comparison places the combined procedure below licensed-sector practice, but it is not a measure of the gap between sectors. The corporate series involves blade implantation alone, in employed patients who receive continuous aftercare. Our figure covers two operations on patients who often cannot afford to return for review. An adequate licensed comparator for the combined procedure does not exist, because corporate clinics rarely perform it.

5. Limitations

This is a retrospective audit of records that the clinics kept for their own purposes. The three clinics chose to take part and are likely to be among the better-organised in Chiba, so the success rate may be higher than in the sector as a whole. Fourteen of 72 patients (19%) had no 18-month visit. The worst-case analysis sets a lower bound, but the true success rate among them is unknown, and any deaths from complications may have been recorded without a cause. Visit notes survived for 49 of the 58 analysed patients, and outcomes for the other nine depend on clinic summaries. Assigning each case to a single primary site makes the analysis simpler but loses information in the two cases with complications at both sites. The number of patients is too small for a clinic comparison with adequate power or for adjustment for patient-level factors. The licensed-sector benchmark comes from a different procedure and a different population, and it is useful only as rough context.